Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

MONALEESA-7 Sets New Standard of Care for Premenopausal Women with Advanced Breast Cancer

TON - August 2019, Vol 12, No 4 - Breast Cancer
Phoebe Starr

Chicago, IL—The addition of the cyclin-dependent kinase (CDK)4/CDK6 inhibitor ribociclib to standard endocrine therapy significantly extended overall survival (OS) compared with endocrine therapy alone in premenopausal women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, according to results of the phase 3 MONALEESA-7 clinical trial, presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.

MONALEESA-7 is the first study to demonstrate significantly longer OS in patients who received a CDK4/CDK6 inhibitor plus endocrine therapy combination versus endocrine therapy alone as initial therapy for advanced breast cancer, and likely represents a new standard of care in this population.

“This is the first study to show improvement for any targeted therapy when used with first-line [endocrine therapy] for advanced breast cancer. MONALEESA-7 was the first phase 3 trial with a CDK4/6 inhibitor [conducted] exclusively in premenopausal patients, and use of ribociclib as front-line therapy significantly prolonged survival, which is good news for women with this terrible disease,” said lead investigator Sara A. Hurvitz, MD, Medical Oncologist, Jonsson Comprehensive Cancer Center, University of California, Los Angeles.

ASCO Expert Harold J. Burstein, MD, PhD, Associate Professor of Medicine, Harvard University, Cambridge, MA, and Medical Oncologist, Dana-Farber Cancer Institute and Brigham & Women’s Hospital, Boston, commented on this study at a press conference. “Advanced breast cancer in premenopausal women can be very aggressive. It is important and encouraging to see a targeted therapy that significantly increases survival for younger women.”

Ribociclib is approved by the US Food and Drug Administration in combination with an aromatase inhibitor for the treatment of pre- and perimenopausal women with HR-positive, HER2-negative advanced breast cancer.

The MONALEESA-7 trial randomized 672 premenopausal women with HR-positive, HER2-negative advanced breast cancer to goserelin (Zoladex) plus either ribociclib (N = 335) or placebo (N = 337). All participants also received either a nonsteroidal aromatase inhibitor or tamoxifen.

Median follow-up was 34.6 months. At interim analysis data cutoff (November 2018), treatment was ongoing in 35% of patients in the ribociclib arm and 17% of patients in the placebo arm. Dr Hurvitz said the majority of patients who ended treatment had disease progression.

Patients receiving ribociclib plus endocrine therapy had a significantly longer median OS than patients receiving placebo plus endocrine therapy (not reached vs 40.9 months; P = .00973). OS analysis showed that “there was a 29% relative reduction in risk of death [in patients in the ribociclib arm],” Dr Hurvitz said. A consistent OS benefit was observed across all subgroups.

After 42 months of treatment, 70.2% of women in the ribociclib arm were alive versus 46% of those in the placebo arm.

Median progression-free survival (PFS) was 23.8 months in the ribociclib arm versus 13 months in the placebo arm.

“The benefit of ribociclib extended beyond the initial treatment based on the time-to-subsequent chemotherapy and PFS2,” said Dr Hurvitz. PFS2 was defined as time from random selection to progression on the next line of therapy or death. The rate of PFS2 was significantly higher with ribociclib (P = .00973).

After 15 months of follow-up, adverse events in the ribociclib arm remained consistent with the drug’s known safety profile. Grade 3 or 4 events of special interest in the ribociclib and placebo arms were neutropenia (63.5% ribociclib vs 4.5% placebo), hepatobiliary toxicity (11.0% ribociclib vs 6.8% placebo), and prolonged QT interval (1.8% ribociclib vs 1.2% placebo).

Formal discussant Angelo Di Leo, MD, PhD, Department Head, Sandro Pitigliani Medical Oncology Unit, and Chair, Oncology Department, Hospital Prato, Istituto Toscano Tumori, Italy, said, “The MONALEESA-7 results are now setting a new standard of care for patients who are endocrine-therapy naïve. I think that this is now a population where we should consider combination of a CDK4/6 inhibitor plus endocrine therapy as a new standard of care.”

“My personal opinion is that this result should be expanded also to the menopausal population. The endocrine-sensitive population is the population who relapsed after at least 1 year from the end of adjuvant endocrine therapy,” Dr Di Leo added.

Related Items
Long-Term Data Confirm Survival Benefit for Pembrolizumab in Advanced NSCLC
Phoebe Starr
Web Exclusives published on November 25, 2019 in Lung Cancer
Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care
Phoebe Starr
Web Exclusives published on October 28, 2019 in ESMO, Breast Cancer
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Web Exclusives published on October 22, 2019 in Breast Cancer, FDA Updates, In the News, Multiple Myeloma, Pediatric Cancer
Reduced-Intensity Chemotherapy for Frail Elderly Patients with Advanced Gastroesophageal Cancer
Phoebe Starr
TON - October 2019, Vol 12, No 5 published on October 7, 2019 in Geriatric Cancer
Fixed-Duration Venetoclax plus Obinutuzumab New Standard of Care for Front-Line Treatment of Patients with CLL and Comorbidities
Phoebe Starr
TON - October 2019, Vol 12, No 5 published on October 7, 2019 in Leukemia
Studies Show ACA Reduces Disparities and Increases Access to Earlier Diagnosis and Treatment
Phoebe Starr
TON - August 2019, Vol 12, No 4 published on August 6, 2019 in ASCO
Osimertinib plus Savolitinib Promising for Non–Small-Cell Lung Cancer with MET-Driven Resistance
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Lung Cancer
High Tumor Mutation Burden Predictive Biomarker for Survival in Metastatic Non–Small-Cell Lung Cancer
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Lung Cancer
Gilteritinib a New Standard of Care for Relapsed or Refractory AML with FLT3 Mutation
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Leukemia
Infigratinib a Novel, Potent Selective TKI Targeting FGFR Fusions in Different Tumor Types
Phoebe Starr
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in Emerging Therapies
Last modified: September 9, 2019